Search - tctmd.com

Displaying 101 - 120 of 2724

Sort: Relevancy | Date

Presentation TCT 2016

Debate: TAVR for Low Risk Patients Is It time? NO, We Dont Yet Know if Its as Durable as Surgical AVR!

Presenter: Russell A. Brandwein, Isaac George

October 30, 2016

Presentation TCT 2016

Debate: TAVR for Low Risk Patients Is It time? YES, the Data Is Sufficient and Our Patients Want It!

Presenter: Russell A. Brandwein, Susheel K. Kodali

October 30, 2016

Presentation TCT 2016

Flash Debate: Counterpoint Stay the Course: We Need the Next Round of Low-Risk Randomized TAVR Studies AND Long-Term Follow-up to Justify Changes!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Lars G. Svensson

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Michael J. Mack

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates I - The UK All-Comer TAVI Study

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Neil E. Moat

October 30, 2016

Presentation TCT 2016

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Martin B. Leon

October 30, 2016

Presentation TCT 2016

An Interesting Alternative: The New WikiRecs for TAVR Use in Lower Risk Patients

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Catherine M. Otto

October 30, 2016

News Conference News TCT 2016

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

Yael L. Maxwell

October 30, 2016

Presentation TCT 2016

First Debate: Should The Low Surgical Risk Patient With Degenerative MR Be Offered Mitraclip? Absolutely Not - In No Universe Would That Be Considered Acceptable Care!

Presenter: James S. Gammie, James B. Hermiller Jr., Alfredo Trento

October 30, 2016

Presentation TCT 2016

First Debate: Should the Low Surgical Risk Patient With Degenerative MR Be Offered Mitraclip? Absolutely! - As Long as He Receives Truly Informed Consent by A Heart Team!

Presenter: James S. Gammie, James B. Hermiller Jr., Brian K. Whisenant

October 30, 2016

Presentation TCT 2016

TAVR 2016: Making the Case For New Patient Subsets (Low Risk, Bicuspid, etc.)

Presenter: Marian C. Hawkey, Patricia Keegan

October 30, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2016

Caitlin E. Cox

October 29, 2016

News Conference News TCT 2016

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

Michael O'Riordan

October 29, 2016

News Conference News TCT 2016

Transcaval TAVR Presents New Option for Patients With Complex Anatomy

Yael L. Maxwell

October 29, 2016

News Conference News TCT 2016

Impella CP Fails to Show Benefit in Exploratory Study of Patients With Severe Cardiogenic Shock

Todd Neale

October 29, 2016

News Daily News

FH Screening Started at Time of Childhood Immunization Feasible and Effective

Michael O'Riordan

October 28, 2016

News Opinion Fellow Talk

My Picks for Fellows Attending TCT 2016

Ankur Kalra

October 27, 2016

News Daily News

Study Explores Possible Mechanism to Explain Air Pollution-CVD Link

Todd Neale

October 27, 2016

News Daily News

New Guideline Gives the Greenlight to Calcium Supplements

Caitlin E. Cox

October 26, 2016

Advertisement

Debate: TAVR for Low Risk Patients Is It time? NO, We Dont Yet Know if Its as Durable as Surgical AVR!

Debate: TAVR for Low Risk Patients Is It time? YES, the Data Is Sufficient and Our Patients Want It!

Flash Debate: Counterpoint Stay the Course: We Need the Next Round of Low-Risk Randomized TAVR Studies AND Long-Term Follow-up to Justify Changes!

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Low-Risk Studies: Design and Updates I - The UK All-Comer TAVI Study

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

An Interesting Alternative: The New WikiRecs for TAVR Use in Lower Risk Patients

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

First Debate: Should The Low Surgical Risk Patient With Degenerative MR Be Offered Mitraclip? Absolutely Not - In No Universe Would That Be Considered Acceptable Care!

First Debate: Should the Low Surgical Risk Patient With Degenerative MR Be Offered Mitraclip? Absolutely! - As Long as He Receives Truly Informed Consent by A Heart Team!

TAVR 2016: Making the Case For New Patient Subsets (Low Risk, Bicuspid, etc.)

TCTMD’s Top 10 Most Popular Stories for October 2016

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

Transcaval TAVR Presents New Option for Patients With Complex Anatomy

Impella CP Fails to Show Benefit in Exploratory Study of Patients With Severe Cardiogenic Shock

FH Screening Started at Time of Childhood Immunization Feasible and Effective

My Picks for Fellows Attending TCT 2016

Study Explores Possible Mechanism to Explain Air Pollution-CVD Link

New Guideline Gives the Greenlight to Calcium Supplements

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content